Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR – Get Free Report) and Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Profitability
This table compares Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Synergy CHC Corp. (Uplisting) | N/A | N/A | N/A |
Mind Medicine (MindMed) | N/A | -47.56% | -35.55% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed), as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Synergy CHC Corp. (Uplisting) | 0 | 0 | 1 | 1 | 3.50 |
Mind Medicine (MindMed) | 0 | 0 | 10 | 3 | 3.23 |
Institutional & Insider Ownership
27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 2.3% of Mind Medicine (MindMed) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed)”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Synergy CHC Corp. (Uplisting) | $26.01 million | 1.19 | N/A | N/A | N/A |
Mind Medicine (MindMed) | N/A | N/A | -$95.73 million | ($2.08) | -3.05 |
Synergy CHC Corp. (Uplisting) has higher revenue and earnings than Mind Medicine (MindMed).
Summary
Mind Medicine (MindMed) beats Synergy CHC Corp. (Uplisting) on 5 of the 9 factors compared between the two stocks.
About Synergy CHC Corp. (Uplisting)
Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Receive News & Ratings for Synergy CHC Corp. (Uplisting) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy CHC Corp. (Uplisting) and related companies with MarketBeat.com's FREE daily email newsletter.